AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Hybrid Flagellin as a Novel T Cell Independent Vaccine Scaffold

Technology Application

This hybrid flagellin vaccine scaffold may be used to vaccinate individuals with less robust immune systems, including those in the early perinatal period, in people suffering from various T cell immunodeficiency disorders (HIV-AIDS, DiGeorge syndrome), patients undergoing chemotherapy, as well as elderly patients with sluggish adaptive immunity.

Detailed Technology Description

None

Application No.

20180169205

Others

Other Information

Related Publication:

Bennett, K. M. et al. Hybrid Flagellin as a T Cell Independent Vaccine Scaffold. BMC Biotechnol. 15, 71 (2015).

Images

hiFLC forming stable filaments

Background

Vaccines are biological products that are able to establish resistance to specific antigens (diseases) in our bodies, through stimulating the immune system and creating antibodies. While traditional types of vaccines are based on weak live virus, killed virus or bacteria, newer versions are toxoid-based, or genetically engineered (including engineered microbes, subunit vaccines, conjugate vaccines, DNA vaccines, and vector vaccines). Vaccines have a total market size of around $32 billion (2016). This market is estimated to reach the level of nearly $48 billion by 2021, resulting in a compound annual growth rate (CAGR) of 8.3%.

Tech ID/UC Case

24323/2014-912-0

Related Cases

2014-912-0

Country/Region

USA

For more information, please click Here